BOLT's logo.
Ticker Symbol: BOLT

Bolt Biotherapeutics Inc

$9.66 - 22-07-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001641281

Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach combines an antibody that targets a tumor antigen with an immune stimulant that triggers an innate and adaptive immune response in the tumor microenvironment. These systemically-delivered Boltbody ISACs are designed to target tumor cells for elimination by myeloid cells, which are then activated and recruit the adaptive immune system in the anti-tumor response. This leads to the conversion of immunologically "cold" tumors to "hot" tumors. Bolt’s lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to one of Bolt’s proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. Bolt is also advancing BDC-2034, a Boltbody ISAC targeting CEA, and a pipeline of other immuno-oncology products.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 640 Galveston Drive
Tags: N/A


Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $1.03
Change: $0.02 ( 1.98%)
Days Range: $0.99 - $1.06
Beta: 0.92
52wk. High: $2.02
52wk. Low: $0.89
Ytd. Change -18.79%
50 Day Moving Average: $1.04
200 Day Moving Average: $1.36
Shares Outstanding: 37950986


Market Cap: 3.9B
PE Ratio: -
EPS (TTM): 0


Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A